GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » 3-Year ROIIC %

Medical Developments International (ASX:MVP) 3-Year ROIIC % : 76.80% (As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Medical Developments International 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Medical Developments International's 3-Year ROIIC % for the quarter that ended in Jun. 2024 was 76.80%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Medical Developments International's 3-Year ROIIC % or its related term are showing as below:

ASX:MVP's 3-Year ROIIC % is ranked better than
87.17% of 998 companies
in the Drug Manufacturers industry
Industry Median: 0.915 vs ASX:MVP: 76.80

Medical Developments International 3-Year ROIIC % Historical Data

The historical data trend for Medical Developments International's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medical Developments International 3-Year ROIIC % Chart

Medical Developments International Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.84 -57.17 -167.35 706.84 76.80

Medical Developments International Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -167.35 - 706.84 - 76.80

Competitive Comparison of Medical Developments International's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medical Developments International's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Medical Developments International's 3-Year ROIIC % falls into.



Medical Developments International 3-Year ROIIC % Calculation

Medical Developments International's 3-Year ROIIC % for the quarter that ended in Jun. 2024 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -20.999415 (Jun. 2024) - -8.1549469 (Jun. 2021) )/( 41.172 (Jun. 2024) - 57.896 (Jun. 2021) )
=-12.8444681/-16.724
=76.80%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Medical Developments International  (ASX:MVP) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Medical Developments International 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Medical Developments International's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medical Developments International Business Description

Traded in Other Exchanges
N/A
Address
4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International Headlines

From GuruFocus

Roundhill Announces Two Fund Closures

By PRNewswire PRNewswire 03-18-2022